2.Oh DY, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8):EVIDoa2200015. doi:10.1056/EVIDoa2200015 3.FDA approves durvalumab for locally advanced or metastatic biliary tract cancer. FDA. September 2, 2022. Accessed ...
cisplatin, and Nab-paclitaxel for resectable BTC.Methods:Resectable, treatment-nave BTC patients (pts) were enrolled and administered 3 cycles of neoadjuvant durvalumab (1000mg, iv, d1, q3w) + GAP (gemcitabine 1000mg/m2, cisplatin 25mg/m2, Nab-paclitaxel 100mg/m2, d1, d8, 21d cycle). ...
药物类型 单克隆抗体 别名 Durvalumab (Genetical Recombination)、Durvalumab (genetical recombination) (JAN)、Durvalumab (USAN/INN) + [10] 靶点 PDL1 作用机制 PDL1抑制剂(程序性死亡配体1抑制剂) 治疗领域 肿瘤消化系统疾病呼吸系统疾病+ [12] 在研适应症 ...
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8):EVIDoa2200015. doi:10.1056/EVIDoa2200015Recent Videos Survival Gains and Challenges: The CROSS Trial in GEJ Cancer The Lasting Impact of the CROSS Trial on GEJ Cancer Care Dostarlimab's Promise in...
IMFINZI is used to treat adults witha type of cancer called BTC,including cancer of the bile ducts (cholangiocarcinoma) and gallbladder cancer. IMFINZI may be used in combination with chemotherapy medicines gemcitabine and cisplatin when your BTC has spread to nearby tissues (locally advanced),orha...
The FDA has approved durvalumab (Imfinzi) in combination with gemcitabine and cisplatin in adult patients with locally advanced or metastatic biliary tract cancers.
Gemcitabine and cisplatin plus durvalumab are being evaluated in the phase 3, TOPAZ-1 study (NCT03875235) as first-line treatment in patients with advanced biliary tract cancer. Funding:AstraZeneca; National Research Foundation of Korea (Grant No. 2021R1A2C2007430). 展开 ...
IMFINZI, in combination with gemcitabine and cisplatin, is indicated for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC). Hepatocellular Carcinoma IMFINZI, in combination with tremelimumab-actl, is indicated for the treatment of adult patients with unresectab...
BTCs=biliary tract cancers; CI=confidence interval; CT=chemotherapy; gem-cis=gemcitabine-cisplatin; HCC=hepatocellular carcinoma; mNSCLC=metastatic non-small cell lung cancer; NSCLC=non-small cell lung cancer; Q3W=every 3 weeks; Q4W=every 4 weeks; SCLC=small cell lung cancer; uHCC=unresectable...
1. FDA approves durvalumab for locally advanced or metastatic biliary tract cancer. News release. September 2, 2022. Accessed September 2, 2022. https://bit.ly/3Qd2Kq 2. Oh DY, He AR, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary t...